Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.86 |
| ▸ | NPC1 | O15118 | 4/20 | 0.86 |
| ▸ | POLB | P06746 | 4/20 | 0.86 |
| ▸ | LMNA | P02545 | 4/20 | 0.86 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.86 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.74 |
| ▸ | MEN1 | O00255 | 5/20 | 0.74 |
| ▸ | AHR | P35869 | 1/20 | 0.74 |
| ▸ | CASP6 | P55212 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 7/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2421809 | 0.93 | LMNA (0.83) | RAB9ACYP1A2CYP2C9NPC1POLB | |
| SCHEMBL13856816 | 0.91 | LMNA (0.76) | RAB9ACYP1A2CYP2C9NPC1POLB | |
| SCHEMBL14104700 | 0.88 | RAB9A (0.69) | RAB9ACYP1A2CYP2C9NPC1POLB | |
| SCHEMBL2420953 | 0.88 | RAB9A (0.68) | RAB9ACYP1A2CYP2C9NPC1POLB | |
| SCHEMBL13959573 | 0.87 | RAB9A (0.76) | RAB9ACYP1A2CYP2C9NPC1POLB | |
| SCHEMBL12326646 | 0.85 | RAB9A (0.72) | RAB9ACYP1A2CYP2C9NPC1POLB | |
| SCHEMBL12325958 | 0.85 | RAB9A (0.72) | RAB9ACYP1A2CYP2C9NPC1POLB | |
| SCHEMBL12326650 | 0.85 | RAB9A (0.76) | RAB9ACYP1A2CYP2C9NPC1POLB | |
| SCHEMBL2423434 | 0.85 | RAB9A (1.00) | RAB9ACYP1A2CYP2C9NPC1POLB | |
| SCHEMBL12325949 | 0.84 | RAB9A (0.71) | RAB9ACYP1A2CYP2C9NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436031-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110230523-A1 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230523-A1 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20090131401-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131401-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7405235-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405235-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1524974-A4 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARM INNC (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1742637-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Paratek Pharmaceuticals, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20060160799-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006076009-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| EP-1558341-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Paratek Pharmaceuticals, Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20050124678-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| EP-1524974-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Paratek Pharmaceuticals, Inc. (US) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004041209-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004001058-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| US-20030229065-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | RAB9A 4067/4885CYP1A2 3557/4885CYP2C9 3774/4885 |
| US-20090131401-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | RAB9A 4067/4885CYP1A2 3557/4885CYP2C9 3774/4885 |
| US-20060160799-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | RAB9A 4067/4885CYP1A2 3557/4885CYP2C9 3774/4885 |
| US-20110230523-A1 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JUN, CREBBP, TFEB | RAB9A 4067/4885CYP1A2 3557/4885CYP2C9 3774/4885 |
| US-20030229065-A1 | Transcription factor modulating compounds and methods of use thereof | RELA, ATF4, JUN | RAB9A 4484/4885CYP1A2 4268/4885CYP2C9 4741/4885 |
| US-20050124678-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | RAB9A 4067/4885CYP1A2 3557/4885CYP2C9 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.